強気
$85.67
シナリオ価格
$271.175
-5.396 (-1.99%)終値時点
Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
Illumina Inc is a good buy right now, trading at $278.17 with a strong year-to-date change of +107.05%. The RSI is at 59.91, indicating bullish momentum, and the forward P/E ratio is 40.32, suggesting growth potential. However, insider selling has increased by 17343.19%, which is a significant risk to consider.
BofA
$168
2026-10-09
BofA
2026-10-09
目標株価
$168
Barclays
$200
2026-10-07
Barclays
2026-10-07
目標株価
$200
RBC Capital
$310
2026-10-05
RBC Capital
2026-10-05
目標株価
$310
Guggenheim
$305
2026-10-01
Guggenheim
2026-10-01
目標株価
$305
Leerink
$300
2026-09-29
Leerink
2026-09-29
目標株価
$300
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。
Illumina Launches BioInsight Platform for Genomic Insights

Illumina to Release Q3 2026 Financial Results

Illumina Launches SpliceAI2 Model, Enhancing Variant Identification Capabilities

Market Outlook: Tech Stock Dynamics and Investment Opportunities

Three Reasons Why Grail's Stock is Soaring
Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Illumina Inc is a good buy right now, trading at $278.17 with a strong year-to-date change of +107.05%. The RSI is at 59.91, indicating bullish momentum, and the forward P/E ratio is 40.32, suggesting growth potential. However, insider selling has increased by 17343.19%, which is a significant risk to consider.
18 analysts cover ILMN: 11 rate it Buy, 6 Hold and 1 Sell. The average price target is 133.54.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。